Bristol-Myers Squibb Company (BMY)
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $55.26, indicating a -2.4% shift from the previous trading day.
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds
BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 56.5% of revenues, temporarily offsetting legacy declines while lending credibility to the thrice raised FY2025 guidance. Otherwise, BMY faces numerous Patent cliffs for Opdivo/Eliquis and the Medicaid headwinds, which may pressure FY2026 results/cash flow generation.
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY and overtaking legacy drugs, supporting a bullish outlook. Despite modest 3% total revenue growth, BMY maintains robust margins, strong cash flow, and a 4.65% dividend yield, enhancing its defensive appeal.
